Table 1 –

Published meta-analyses as of 2016 investigating the association between NAFLD and cardiovascular events and/or mortality

Authors, year [Ref.]	Inclusion/exclusion criteriaa	NAFLD diagnosis	Number of studies (Total, reporting CV mortality)	Sample size (Total, with NAFLD)	Heterogeneity (I2 statistic)b	Pooled point estimate for CVD-related mortality, (95% CI)
Targher et al., 2016 [5]	Any cross-sectional, prospective or retrospective study Any language	Imaging or histology only	Total: 16 CV mortality: 7	Total participants: 34,043 No. with NAFLD: 12,381	90%	OR 1.31, (0.87–1.97)
Wu et al., 2016 [68]	Any cross-sectional, prospective, or retrospective study events or mortality Any language exclusion	Imaging, histology, or labs	Total: 34 CV mortality: 5	Total participants: 164.494 No. with NAFLD: not reported	64.9%	HR 1.10, (0.86–1.41)
Haddad et al., 2017 [47]	Prospective studies only Control group without NAFLD English language only	Imaging only	Total: 6 CV mortality: 2	Total participants: 25,837 No. with NAFLD: 5,953	0%	RR 1.46, (1.30–1.64)c
Liu et al., 2019 [69]	Excluded studies with patients undergoing LT or bariatric surgery	Imaging or histology	Total: 14 CV mortality: 7	Total participants: 498,501 No. with NAFLD: 95,111	57.5%	HR 1.13, (0.92–1.38)

^aThe following inclusion/exclusion criteria were common to all meta-analyses: adult (>18 years) participants only and included studies reported association between NAFLD and CV mortality,

^bI² statistic only for subset of studies with outcome of CV mortality

^cReported RRs are unadjusted. The original studies reported adjusted HRs and showed no statistical increase in CV mortality.